Community Research and Development Information Service - CORDIS

FP7

GI-NEU Report Summary

Project ID: 324476
Funded under: FP7-PEOPLE
Country: Greece

Periodic Report Summary 1 - GI-NEU (IMPACT OF COLOSTRUM-BASED NEUTRACEUTICALS ON FUNCTIONAL GASTROINTESTINAL DISORDERS)

1. Summary description of project context and objectives
The occurrence of functional gastrointestinal disorders (FGID) is high. FGIDs’ are among the most common medical conditions seen in primary care as well as in gastroenterology specialty clinics accounting for 41% of diagnoses in specialty practices. European data demonstrates that 58% of adults report at least one FGID symptom every three months. For instance, in the UK FGID is the second most common cause of death and has increased by 25% in the last ten years. A primary diagnosis of FGID in Europe leads to over 70 million outpatient visits, resulting in total FGID costs of 120 billion euro per year. Hence, it is not surprising that the health and environment progress assessment of the World Health Organisation (WHO) Regional Office for Europe recognizes the significant reduction of the morbidity and mortality arising from gastrointestinal disorders as a regional priority goal.

The GI-Neu project, funded by the 7th Framework Programme of the European Commission, is creating a multiannual joint programme of collaboration between research-intensive non-commercial (academic) and commercial (industry) organisations to increase knowledge on the effects of colostrum-based neutraceuticals on FGID. The vast majority of attempts to address FGID to date have been led by either the public or the private sector alone. The GI-Neu project is designed to exploit the complimentary expertise of non-commercial and commercial organisations through knowledge sharing and transfer between sectors. This will be achieved by staff secondments of researchers from outside the partnership for the purpose of networking, training activities, workshops, and joint research. Through these activities, the GI-Neu project is fostering mutual understanding of the different cultural settings and skill requirements of the non-commercial and commercial sectors, encouraging entrepreneurship and long-term intersectoral collaboration regarding the effects of colostrum-based neutraceuticals on FGID. Eventually, the aim of this partnership is to translate creative ideas into innovative products and processes that can efficiently address existing challenges on gastrointestinal issues.

According to the Annex I, a total of 9 Deliverables must be reported. These are:

1. D.15.1: Minutes of the Start-up Meeting by CERTH.
2. D.2.1: Training activity report by IMED.
3. D.5.1: Workshop report by UNITUS.
4. D.1.1: Networking exchange report by CERTH.
5. D.3.1: Training activity report by IMED.
6. D.1.2: Networking exchange report by IMED.
7. D.6.1: Workshop report by IMED.
8. D.4.1: Training activity report by KSL.
9. D.15.3: Midterm report by CERTH.

At the time that this report was prepared, the D.15.1, D.1.1, D.2.1, D.5.1, D.3.1, D.1.2, D.6.1, and D.15.3 have been completed and are attached in this Periodic Report. On February 2014 one of the dissemination activities that is part of D.14.1 (from CERTH to KSL) was conducted as well. On December 2014 one of the dissemination activities that is part of D.14.1 (from UNITUS to IMEDICA) was conducted as well. Also on July 2015 one of the dissemination activities that is part of D.14.1 (from CERTH to KSL) was conducted as well. The training activity which comprises D.4.1 has been planned for next year.

The project website (www.gi-neu.eu) is functional and continuously updated with all the projects’ news and actions, while we have also initiated a Quarterly Project Newsletter which is electronically dispatched to all project partners, the project website, and to interested parties across Europe, and we have created a video for the project that is posted on the project website and on other social media.
Contact Details
Andreas D. Flouris, PhD
FAME Laboratory
Institute of Research and Technology Thessaly
Centre for Research and Technology Hellas
Karies, Trikala, 42100, Greece
E-mail: aflouris0@gmail.com

Contact

Georgia Pahlitzanakis, (Head of Administration)
Tel.: +302421096743
Fax: +302421096750
E-mail

Subjects

Life Sciences
Record Number: 195397 / Last updated on: 2017-03-13